

SHEET 1 OF 4

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

P26,488-A USA

Application Number

09/386,709

Applicant(s)

David Brayden

Filing Date

August 31, 1999

Group Art Unit

1645

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AE

D.S. Johnston, et al., "Preparation of Liposomes", Liposome Technology, Volume I, pages 123-129

AF

Catherine Ferreccio, et al., "The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age", The Pediatric Infectious Disease Journal, Vol. 10, No. 10, October 1991, pages 764-771

AG

John D. Clemens, et al., "Impact of Haemophilus influenzae Type b Polysaccharide-Tetanus Protein Conjugate Vaccine on Responses to Concurrently Administered Diphtheria-Tetanus-Pertussis Vaccine", JAMA, February 5, 1992, Vol. 267, No. 5, pages 673-678

AH

Kingston H. G. Mills, et al., "Cell-Mediated Immunity to Bordetella pertussis: Role of Th1 Cells in Bacterial Clearance in a Murine Respiratory Infection Model", Infection and Immunity, February 1993, Vol. 61, No. 2, pages 399-410

AI

K. J. Maloy, et al., "Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles", Immunology, 1994, Vol. 81, pages 661-667

AJ

Edwin L. Anderson, et al., "Acellular pertussis vaccines in infants: evaluation of single component and two-component products", Center for Vaccine Development, Division of Infectious Diseases, March 19, 1993, 4 pages

AK

Werner Rubas, et al., "An Integrated Method to Determine Epithelial Transport and Bioactivity of Oral Drug Candidates in Vitro", Pharmaceutical Research, Vol. 13, No. 1, 1996, pages 23-26

AL

Roberta Shahin, et al., "Adjuvant activity and Protective Immunity Elicited by Bordetella pertussis Antigens Encapsulated in Poly(DL-Lactide-Co-Glycolide) Microspheres", Infection and Immunity, April 1995, Vol. 63, No. 4, pages 1195-1200

AM

J. Terry Ulrich, et al., "Monophosphoryl Lipid A as an Adjuvant, Past Experiences and New Directions", Chapter 21, pages 495-522

AN

E.S. Cahill, et al., "Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles", Vaccine, 1995, Vol. 13, No. 5, pages 455-462

AO

Anne Morre, et al., "Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells", Vaccine, October 29, 1995, Vol. 13, pages 1-11

AP

Ying Men, et al., "A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide", Vaccine, Vol. 13, No. 7, pages 683-689

MINER

DATE CONSIDERED

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

P26,488-A USA

Application Number

09/386,709

Applicant(s)

David Brayden

Filing Date

August 31, 1999

Group Art Unit

1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL		
	AQ	Manisha P. Desai et al., "Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size", Pharmaceutical Research, Vol. 13, No. 12, 1996, pages 1838-1841
	AR	K. D. Newman et al., "Ovalbumin peptide encapsulated in Poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response", Journal of Controlled Release, 54, 1998, pages 49-59
	AS	Siobhan McClean et al., "Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia", European Journal of Pharmaceutical Sciences, 1997, 3 pages
	AT	MA Coyle et al., "In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine", Gene Therapy 1998, Vol. 5, pages 645-651
	AU	M.Ryan et al., "Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children", Immunology, Vol. 93, 1998, pages 1-10
	AV	J. Nugent et al., "Design and delivery of non-parenteral vaccines", Journal of Clinical Pharmacy and Therapeutics, Vol. 23, 1998, pages 257-285
	AW	Graham A. W. Rook et al., "Give us this day our daily germs", View Point - Immunology Today, Vol. 19, No. 3, March 1998, pages 113-120
	AX	Kimberley D. Newman et al., "Delivery of MUC1 Mucin Peptide by Poly(d,l-lactic-co-glycolic acid) Microspheres Induces Type 1 T Helper Immune Responses", Journal of Pharmaceutical Sciences, Vol. 87, No. 11, November 1998, pages 1421-1427
	AY	Harokopakis et al., "Effectiveness of Liposomes Possessing Surface-Linked Recombinant B Subunit of Cholera Toxin as an Oral Antigen Delivery System", Vaccine Delivery, page 20, 2nd paragraph
	AZ	David J. Brayden et al., "Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines", PSTT, Vol. 1, No. 7, October 1998, pages 291-298
	BA	Jeffrey L. Cleland, "Single-administration vaccines: controlled-release technology to mimic repeated immunizations", TIBTECH, January 1999, Vol. 17, pages 25-29
	BB	Maria Tobio et al., "A Novel System Based on a Poloxamer/PLGA Blend as a Tetanus Toxoid Delivery Vehicle", Pharmaceutical Research, Vol. 16, No. 5, 1999, pages 682-688

MINER

DATE CONSIDERED

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

P26,488-A USA

Application Number

09/386,709

Applicant(s)

David Brayden

Filing Date

August 31, 1999

Group Art Unit

1645

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BC

Khushroo E. Shroff et al., "Potential for plasmid DNAs as vaccines for the new millennium", PSTT, Vol. 2, No. 5, May 1999, pages 205-213

BD

Prosper N. Boyaka et al., "IL-12 Is an Effective Adjuvant for Induction of Mucosal Immunity", The Journal of Immunology, 1999, pages 122-128

BE

Mariarosaria Marinaro et al., "Use of Intranasal IL-12 to Target Predominantly Th1 Responses to Nasal and Th2 Responses to Oral Vaccines Given with Cholera Toxin", The Journal of Immunology, 1999, pages 114-121

MINER

DATE CONSIDERED

AMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.

8/25/03

ease type a plus sign (+) inside this box →

PTO/SB/O8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheet as necessary)

Complete if Known

Application Number	09/386,709
Filing Date	August 31, 1999
First Named Inventor	David J. Brayden
Group Art Unit	1641
Examiner Name	J. Graser
Attorney Docket Number	P26,488-A USA

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	AA	5,075,109		TICE et al.	12/24/1991
	AB	5,362,478		DESAI et al.	11/08/1994
	AC	5,303,527		MALICK et al.	02/28/1995
	AD	5,417,886		REID et al.	05/23/1995
	AE	5,439,686		DESAI et al.	08/08/1995
	AF	5,441,739		KOSSOVSKY et al.	08/15/1995
	AG	5,529,777		ANDRIANOV et al.	06/25/1996
	AH	5,603,960		O'HAGAN et al.	02/18/1997
	AI	5,631,263		PORTOGHESE, et al.	05/20/1997
	AJ	5,674,534		ZALE, et al.	10/07/1997
	AK	5,709,879		BARCHFELD, et al.	01/20/1998
	AL	5,807,757		ANDRIANOV, et al.	09/15/1998
	AM	5,871,747		GENGOUX-SEDLIK et al.	02/16/1999
	AN	5,885,586		ECKHARDT et al.	03/23/1999
	AO	5,885,587		ECKHARDT et al.	03/23/1999
	AP	5,895,655		ECKHARDT et al.	04/20/1999
	AQ	5,897,867		ECKHARDT et al.	04/27/1999
	AR	6,004,763		GENGOUX et al.	12/21/1999
	AS	6,309,669 B1		SETTERSTROM et al.	10/30/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			
	AT		EP 0 154 902		NEURATH, A.R. et al.	02/28/1985	
	AU		WO 86/06635		BIO-TECHNOLOGY AUSTRALIA PTY. LTD., RUSSELL-JONES, G. et al.	11/20/1986	
	AV		EP 0 266 119B1		SOUTHERN RESEARCH INSTITUTE, UNIVERSITY OF ALABAMA AT BIRMINGHAM, TICE, T.R., et al.	10/21/1987	
	AW		EP 0 333 523		THE UAB RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTE, TICE, T. et al.	03/20/1989	
	AX		EP 0 706 792		THE UAB RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTE, TICE, T., et al.	03/20/1989	
	AY		WO 90/04963		DANBIOSYST UK LIMITED, ILLUM, L. et al.	05/17/1990	
	AZ		EP 0 484 621A3		AMERICAN CYANAMID COMPANY, ECKHARDT, T.G.	05/18/1991	
	BA		WO 92/19263		THE USA, REID, R.H. et al.	11/12/1992	
	BB		WO 93/20843		CZINN, S. ET AL.	04/09/1993	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheet as necessary)

Complete if Known

Application Number	09/386,709
Filing Date	August 31, 1999
First Named Inventor	David J. Brayden
Group Art Unit	1641
Examiner Name	J. Graser
Attorney Docket Number	P26,488-A USA

Sheet

2

of

3

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			
JP	BC		WO 93/21950		MEDEVA HOLDINGS BV, ROBERTS, M. et al.	11/11/1993	
	BD		WO 94/15636		CSL LIMITED, COX, J., et al.	12/24/1993	
	BE		WO 94/06472		INSTITUT PASTEUR, GENGOUX, C. et al.	03/31/1994	
	BF		WO 94/08588		CONSERVATOIRE NATIONAL DES ARTS ET METIERS, MORFIN, R.	04/28/1994	
	BG		WO 94/09898		GANDER, B., et al.	05/11/1994	
	BH		WO 94/21289		THE U.S. OF AMERICA, THE SECRETARY OF THE ARMY, REID, R. et al.	09/29/1994	
	BI		WO 95/02416		VIRUS RESEARCH INSTITUTE, ANDRIANOV, A.K. et al.	01/26/1995	
	BJ		WO 95/11008		GENENTECH, INC., CLELAND, et al.	04/27/1995	
	BK		WO 95/11010		GENENTECH, INC., CLELAND, J.L. et al.	04/27/1995	
	BL		EP 0 686 630B1		TAKEDA CHEMICAL INDUSTRIES, LTD., SOHDA, T.	05/06/1995	
	BM		WO 95/13838		GROSS, et al.	05/26/1995	
	BN		WO 95/17167		GANDER, B. et al.	06/29/1995	
	BO		WO 95/35097		UNIVERSITY OF NOTTINGHAM, YEH, et al.	12/28/1995	
	BP		EP 0 737 472A1		LG CHEMICAL LIMITED, LEE, H.	03/15/1996	
	BQ		WO 96/14876		THE REGENTS OF THE UNIVERSITY OF COLORADO, DUKE, R. et al.	05/23/1996	
	BR		WO 96/20698		THE BOARD OF REGENTS, THE UNIV. MICHIGAN, LEVY, R. et al.	07/11/1996	
	BS		WO 97/17613		ELAN CORPORATION, PLC, O'MAHONY, D.	05/15/1997	
	BT		WO 97/31691		THE UNIVERSITY OF KANSAS, SUBRAMANIAM, et al.	09/04/1997	
	BU		WO 97/32572		THE PENN STATE RESEARCH FOUNDATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, EDWARDS, D. et al.	09/12/1997	
	BV		WO 98/51325		CYTOGEN CORPORATION, ELAN CORPORATION, ALVAREZ, V. et al.	11/19/1998	
	BW		WO 98/51825		ELAN CORPORATION, PLC, CYTOGEN CORPORATION, O'MAHONY, D. et al.	11/19/1998	
	BX		WO 98/58668		MICROBIOLOGICAL RESEARCH AUTHORITY, FARRAR, G.H. et al.	12/30/1998	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheet as necessary)

Sheet 3 of 3

Complete if Known: ☐ YES ☒ NO

Application Number	09/386,709
Filing Date	August 31, 1999
First Named Inventor	David J. Brayden
Group Art Unit	1641
Examiner Name	J. Graser
Attorney Docket Number	P26,488-A USA

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JG	BY	ELDRIDGE, J.H. et al., "Controlled Vaccine Release In The Gut-Associated Lymphoid Tissues. I. Orally Administered Biodegradable Microspheres Target The Peyer's Patches", Journal of Controlled Release, 1990, Vol. 11, pp. 205-214	
	BZ	UCHIDA T., et al., "Oral Delivery of Poly(lactide-co-glycolide) Microspheres Containing Ovalbumin as Vaccine Formulation: Particle Size Study", Biol. Pharm Bull, September 1994, Vol. 17, No. 9, pp. 1272-1276	
	CA	KISSEL, T., et al., "Injectable Biodegradable Microspheres for Vaccine Delivery" Microparticulate Systems for the Delivery of Proteins and Vaccines, Marcel Dekker, Inc. (S. COHEN, et al., Editors), 1996, pp. 51-87	
	CB	JONES, D.H. et al., "Orally Administered Microencapsulated Bordetella pertussis Fimbriae Protect Mice from B. pertussis Respiratory Infection", Infection and Immunity, February 1996, Vol. 64, No. 2, pp. 489-494	
	CC	SINGH, M. et al., "Controlled Release Microparticles as a Single Dose Diphtheria Toxoid Vaccine: Immunogenicity in Small Animal Models", Vaccine, February 1998, Vol. 16, No. 4, pp. 346-352	
✓	CD	SINGH, M. et al., "The Preparation and Characterization of Polymeric Antigen Delivery Systems for Oral Administration", Adv. Drug Delivery Rev., December 1, 1998, Vol. 34, No. 2-3, pp. 285-304	

EXAMINER

DATE CONSIDERED

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.